The only dedicated end-to-end, industry led TCR therapy summit is a unique opportunity to delve into the details of TCR development. This technical meeting is a rare opportunity to learn from 20+ industry experts from Ziopharm, Immatics US, TScan Therapeutics and many more. Gain insights on their various approaches and be the first to hear cutting-edge data from this fast-paced industry.
A 23.1% growth rate since 2009 spells progress in the TCR-Based therapies space. This dedicated meeting brings you the industry leaders pushing the bounds of T Cell therapies. With a building number of Phase 1 and Phase 2 trials on the horizon, stay ahead of this booming field at the TCR-based therapies summit.
Covering the most exciting developments and promising clinical data, the TCR-based Therapies Summit will propel your research ahead in 2020 with optimized target identification, supercharged T-cell modifications and insights to the future of manufacturing. For leaders in the TCR space, this is not a meeting to be missed!
April 20-22, 2020
+1 617 455 4188
Conference Only - Earlybirds Available: USD 2999.0,
Conference + 1 Workshop (A or B) - Earlybirds Available: USD 3598.0,
Conference + 2 Workshops (A And B) - Earlybirds Available: USD 4197.0,
Workshops (Individual): USD 599.0
Speakers: Laurence Cooper, Chief Executive Officer, Ziopharm Oncology, Robert Hofmeister, Chief Scientific Officer, TCR2, Cheng Liu, Chief Executive Officer, Eureka Therapeutics, Gavin MacBeath, Chief Scientific Officer, TScan Therapeutics, David Scheinberg, Chairman, Molecular Pharmacology, MSKCC, Dolores Schendel, Chief Executive Officer, Medigene, Pete Smith, Chief Executive Officer, Affinity Bio, Steffen Walter, Chief Scientific Officer, Immatics US